Calliditas Therapeutics US Inc.
Hoboken, NJ
- UEI
- MAZGQDV5PK59
- CAGE
- 95ML3
- Primary NAICS
- 325412 Pharmaceutical Preparation Manufacturing
- SAM.gov registration
- Expired
Company facts
- Self-certified in SAM.gov
- Entity structure
- Corporate Entity (Not Tax Exempt)
- SAM.gov registration date
- Physical address
- 5 Marine View Plaza #304, Hoboken, NJ 07030, USA
Registration and certifications come from SAM.gov and the SBA; company details from public web sources. Updated .
Contract obligations by fiscal year
| Fiscal year | Obligated |
|---|---|
| FY2027 To date | $0 |
| FY2026 | -$255,298 |
| FY2025 | $0 |
| FY2024 | $393,585 |
Contract vehicles
Contract awards
| Award | Agency | Obligated | Awarded |
|---|---|---|---|
| Bulk tarpeyo | Veterans Integrated Service Network 20 (VHA) | $0 | |
| Tarpeyo | Veterans Integrated Service Network 20 (VHA) | $127,649 | |
| Tarpeyo | Veterans Integrated Service Network 20 (VHA) | $10,637 |
Similar vendors
| Vendor | Location | Primary NAICS |
|---|---|---|
| Ascendis Pharma, Inc. | — | 325412 Pharmaceutical Preparation Manufacturing |
| Sobi, Inc. | Waltham, MA | 325412 Pharmaceutical Preparation Manufacturing |
| Radius Health, Inc. | Boston, MA | 325412 Pharmaceutical Preparation Manufacturing |
| Mirum Pharmaceuticals, Inc. | San Mateo, CA | 325412 Pharmaceutical Preparation Manufacturing |
| Incyte Corporation | Wilmington, DE | 325412 Pharmaceutical Preparation Manufacturing |
About the company
Calliditas Therapeutics US Inc. is a foreign-owned, for-profit pharmaceutical company registered in the System for Award Management (SAM) since September 2021. The company specializes in providing pharmaceutical products to the federal government, with a primary focus on supplying TARPEYO, a medication used to treat primary immunoglobulin A nephropathy, a serious renal condition. TARPEYO is specifically designed to address uncontrolled protein in urine for adult patients, representing a targeted therapeutic solution for a complex medical condition.
The company has been awarded multiple federal contract awards exclusively through the Department of Veterans Affairs (VA), with all contracts focused on delivering TARPEYO to VA medical facilities nationwide. These contracts are delivery orders with no specific set-aside designations, ranging in value from $10,637.43 to $382,947.48. Each contract is structured as a firm fixed-price delivery order under the Pharmaceuticals and Drugs (FSS-61-IB) schedule, demonstrating Calliditas Therapeutics US Inc.'s specialized approach to supplying a specific pharmaceutical product to federal healthcare systems. The contracts have consistently targeted VA medical centers and clinics, indicating a concentrated effort to support veterans' healthcare needs through this specialized medication.
Calliditas Therapeutics US Inc. holds two primary federal contract indefinite delivery vehicles (IDVs): a Federal Supply Schedule contract and a Blanket Purchase Agreement (BPA), both awarded by the VA. The Federal Supply Schedule contract, valued at $3.5 million and effective through June 2027, allows for multiple awards under the Pharmaceuticals and Drugs schedule. The BPA, valued at $1,750,000 and effective through April 2026, designates Calliditas Therapeutics US Inc. as the sole approved supplier of TARPEYO to VA medical facilities. These IDVs have been awarded through different VA networks, including the Veterans Integrated Service Network 12 and the National Acquisition Center, and provide a structured mechanism for procuring this specialized pharmaceutical product for veterans with specific renal conditions.
Quick answers
Is Calliditas Therapeutics US Inc. registered in SAM.gov?
Calliditas Therapeutics US Inc.'s SAM.gov registration expired on October 1, 2026.
Which contract vehicles does Calliditas Therapeutics US Inc. hold?
Calliditas Therapeutics US Inc. holds a place on 1 federal contract vehicle: FSS-61-IB.
How much has Calliditas Therapeutics US Inc. received in federal contracts?
Federal contracts obligated $138,287 to Calliditas Therapeutics US Inc. in fiscal years 2023 through 2027.
What is Calliditas Therapeutics US Inc.'s most recent federal award?
Calliditas Therapeutics US Inc.'s most recent federal contract award is Bulk tarpeyo (36C26025F0063), from Veterans Integrated Service Network 20 (VHA), on March 12, 2025.
On GovTribe
See Calliditas Therapeutics US Inc.'s full federal record
- Federal contract awards
- IDV awards
- Contract vehicles
- Funding analysis by agency, NAICS and set-aside
- Similar vendors